Heterocyclic-substituted compounds of the formula
##STR1##
or a pharmaceutically acceptable salt thereof, are disclosed, wherein:
Z is (CH2)n;
##STR2##
wherein R10 is absent; or
##STR3##
wherein R3 is absent;
the single dotted line represents an optional double bond;
the double dotted line represents an optional single bond;
n is 0-2;
Het is an optionally substituted mono-, bi- or tricyclic heteroaromatic group;
B is (CH2)n3, wherein n3
is 0-5, CH2O, CH2S,
CH2NR6, C(O)NR6,
NR6C(O),
##STR4##
optionally substituted alkenyl or optionally substituted alkynyl;
X is O or NR6 when the double
dotted line represents a single bond, or X is H, OH or NHR20
when the bond is absent;
Y is O, S, (H, H), (H, OH) or (H, C1-C6
alkoxy) when the double dotted line represents a single bond, or when the bond
is absent, Y is O, NOR17, (H, H), (H, OH), (H, SH),
(H, C1-C6 alkoxy) or (H, substituted-amino);
R22 and R23 are independently OH, OC(O)R30,
OC(O)NR30R31, or optionally substituted alkyl, alkenyl, alkynyl,
heterocycloalkyl, aryl, cycloalkyl, cycloalkenyl, carbonyl, amino, alkoxy, alkenyloxy,
alkynyloxy, heterocycloalkyloxy, cycloalkyloxy, or cycloalkenyloxy; or R22
and R10, or R23 and R11, can form a carbocyclic
or heterocyclic ring;
and the remaining variables are as described in the specification.
Also disclosed are pharmaceutical compositions containing said compounds and
their use as thrombin receptor antagonists and binders to cannabinoid receptors.
